Efforts are underway to bring to market a vaccine for valley fever, a fungal infection with COVID-like symptoms that occurs in the deserts of the Southwest. The illness is getting more attention as cases rise and a warming climate threatens to spread it through the West.
As the nation awaits a vaccine to end the pandemic, local health departments say they lack the staff, money, tools ― and a unified plan ― to distribute, administer and track millions of vaccines, most of which will require two doses. Dozens of doctors, nurses and health officials interviewed by KHN and The Associated Press expressed their concern and frustration over federal shortcomings.
The nation’s top infectious disease official is confident that an independent panel will base vaccine approval on science, not politics.
Donald Trump accepted his party’s nomination to seek reelection for a second term as president in front of a partisan audience that appeared to largely lack masks and opt against social distancing.
A robust sign-up for flu shots could help head off a nightmare scenario in the coming winter of hospitals stuffed with both COVID-19 patients and those suffering from severe effects of influenza. Plus, no one knows how flu and COVID might interact if a patient got both.
Harbor-UCLA Medical Center serves patients who are especially vulnerable to the coronavirus: They are essential workers, have chronic diseases and are members of underrepresented racial and ethnic groups. When the safety-net hospital kicks off enrollment for its COVID-19 vaccine trial Wednesday, it will look to those patients to participate.
Advocates of cheap and widely available vaccines thought the pandemic might change business as usual. They were wrong.
Polio terrified Americans, and in 1955, when Jonas Salk’s vaccine became available, they snapped it up like candy. Sixty-five years later, COVID is the latest dread virus, but many undercurrents could inhibit its acceptance.
A small allergy clinic in Medford, Oregon, might seem an unlikely place to recruit hundreds of volunteers to test the Moderna vaccine against COVID-19. But its steward has a record of leading hundreds of clinical trials.
Vaccines engineered to protect the public from influenza, hepatitis B, tetanus and rabies are less effective for obese people, leaving them more vulnerable to serious illness. As scientists race to develop a COVID-19 vaccine, experts say obesity could prove an impediment — a sobering prospect for a nation in which nearly half of all adults are obese.
